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A phase II study was designed to evaluate objective response rate and toxicity of fotemustine as single-drug
chemotherapy in non-small-cell lung cancer. Eighty-seven patients with unresectable non-small-cell lung cancer
took part in the study. Seventy-seven were evaluable for response. Of these, 60% had received prior
chemotherapy and 74% had metastatic disease. Moreover, 22 patients had central nervous system metastases
(of whom 12 were evaluable for this site). Treatment consisted of fotemustine 100 mg m 2 administered on
days 1 and 8 followed by a 5 week rest period. Afterwards, responding or stabilised patients received
fotemustine 100 mg m-2 every 3 weeks as a maintenance therapy. Toxicity and quality of life were recorded
during therapy. Thirteen patients (17%; 95% CI 9-25%) had an objective response (11% for pretreated, 26%
for non-pretreated) with a median duration of 22 weeks (range 7-41 weeks). Two objective responses were
observed among the 12 patients with evaluable brain metastases. No response was observed among the 14
patients with adenocarcinoma. Haematological, gastrointestinal, hepatic and renal toxicities were mild to
moderate and manageable. The most frequent biological adverse reactons were delayed thrombocytopenia and
neutropenia. Quality of life did not significantly decrease during the first 6 treatment weeks. Moreover, it
remained stable during the study period in patients with response or stabilisation, whereas it significantly
decreased in patients who experienced progression of the disease. Fotemustine is feasible for single-drug
chemotherapy in non-small-cell lung cancer even though poor prognostic variables such as brain metastases
are present. It can be administered on an outpatient basis and toxicity is moderate and manageable. Thus,
fotemustine can be considered as a putative drug in further combinations.
Chemotherapy is still an experimental treatment in a
majority of patients with non-small-cell lung cancer
(NSCLC) (Hansen, 1988). Combinations of cisplatin and
vinca alkaloids induce a survival improvement in unresec-
table NSCLC when compared with best supportive care.
However, the ratio of the benefit in duration of survival to
the benefit in quality of life (QL) might be suboptimal owing
to the high frequency of toxic events induced by cisplatin-
based regimens. Among NSCLC patients, those who relapse
after first-line chemotherapy or those presenting central ner-
vous system metastases are considered to have poor prog-
nosis and are usually ineligible for cisplatin-based therapy.
Thus, a search for new drugs is required in an attempt to
obtain a survival advantage without inacceptable toxicity,
particularly in patients with poor-prognosis NSCLC.
Fotemustine, a new amino acid phosphonate derivative of
the nitrosourea group, has been recently introduced in the
treatment of human solid malignancies (Avril et al., 1990;
Jacquillat et al., 1990a). This cytotoxic drug induced a 24%
objective response (OR) rate in a phase II study of fotemus-
tine as a single-drug therapy in disseminated malignant
melanoma (Jacquillat et al., 1990a), including patients with
brain metastases (Jacquillat et al., 1990b). This drug has also
been reported to be active in primary brain tumours (Frenay
et al., 1991). In a previous phase II study, we tested fotemus-
tine in the treatment of squamous cell carcinoma using the
100 mg m-2 dosage on a day 1, 8 and 15 regimen followed by
a 5 week rest period, with maintenance therapy thereafter
consisting of a course of 100mg m-2 every 3 weeks (Le
Chevalier et al., 1989). An OR rate of 12% was observed but
the treatment was associated with a 30% grade IV throm-
bopenia toxicity. It has been observed, in a more recent study
of fotemustine 100 mg m-2 in melanoma, that the day 1, day
8 schedule is well tolerated with a similar efficacy (Avril et
al., 1990).
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We report herein a French multicentre phase II study on
fotemustine on day 1 and day 8 in patients with poor-
prognosis advanced NSCLC.
Patients and methods
Eligibility criteria
Patients of both sexes with histologically proven and unresec-
table NSCLC were entered. Inclusion criteria were: age below
75 years; Karnofsky index >60%; baseline leucocytes
4,000 ttl' or more, neutrophils 2,000pl`' or more and
platelets 150,000 l-1 or more; bilirubin, alkaline phos-
phatase, serum glutamic oxaloacetic transaminase (SGOT)
and serum glutamic pyruvic transaminase (SGPT) lower than
twice the normal upper limits; measurable or evaluable
disease; and written informed consent. Staging was carried
out by exhaustive procedure according to the fourth edition
of the UICC-TNM classification and the American Thoracic
Society map of regional pulmonary nodes (Tisi et al., 1982;
Sobin et al., 1987). Patients presenting central nervous system
metastases were eligible, whereas patients for whom bone
metastases were the only evaluable lesions were not included.
Only evolutive lesions (i.e. lesions for which a progression
before inclusion could be documented) were taken as
indicator lesions for chemotherapy response measurement.
Patients who had undergone previous chemotherapy and/or
radiotherapy treatment were eligible if the disease was con-
sidered as evolutive and if 4 weeks or more had elapsed
between the end of the first treatment and entrance into this
study. This delay was prolonged to 8 weeks if haematopoietic
sites had been included in the radiation fields.
Treatment schedule andstudy design
Fotemustine was provided by the Servier International
Research Institute. The compound was administered over a
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60 min intravenous infusion in a 5% glucose solution, which
was protected from light. Induction treatment consisted of
fotemustine 100 mg m2 administered on days 1 and 8 fol-
lowed by a 5 week rest period. During this period, on days 8,
22 and 36 toxic events were recorded according to the World
Health Organization (1979) scale. In particular, the following
parameters were monitored: clinical assessment of overall
toxicity, QL index, blood cell count, hepatic and renal func-
tions. On day 43, the above-mentioned parameters were
recorded again and tumour response was evaluated by
measuring the indicator lesions. Responses were carefully
reviewed by a panel of investigators.
Afterwards, patients for whom an OR was demonstrated
and patients with stable disease underwent a maintenance
chemotherapy consisting of fotemustine 100mgm2 every 3
weeks until progression of the disease or grade III-IV toxi-
city (or both) occurred. Throughout the treatment, reduction
in the administered fotemustine dose was decided on the
basis of both haematological toxicity and hepatic function
tests.
A QL index (Spitzer et al., 1984) was recorded at the time
of inclusion and afterwards on days 8, 22, 36 and 43. In
addition, we assessed five important somatic variables:
appetite, body weight, pain, sleep and fatigue. At each
reassessment, the variables were scored as follows: - 1, 0 and
+1 for impairment, stabilisation and improvement respec-
tively. These variables were included in an original somatic
scale consisting of the sum of the five scores.
Tumour response measurement
Tumour response was assessed using the WHO response
criteria (World Health Organization, 1979). Indicator lesions
were clearly defined at the time of inclusion and the tech-
nique used for measurement was also defined (usually CT
scan). A complete response (CR) was defined as the complete
disappearance of all lesions; a partial response (PR) was
defined as > 50% reduction in the product of the two
longest perpendicular diameters of the indicator lesion for
measurable tumours, or an improvement > 50% for
evaluable-only indicator lesions. A minor response (MR) was
defined as a 25-49% decrease in the measurable indicator
lesion in the product of the two longest perpendicular
diameters of the indicator lesions, whereas stable disease
Table I Patient characteristics
Number
Sex
Median age (range)
Histology
SQC
Ad
LCC
BaC
Adenosquamous
Karnofsky index (KI) (%)
100
90
80
70
Median KI for the whole population
Stage of disease
I and II
III
IV
Previous treatment
None
CT ± surgery ± RT
Other than CT
77
66M/1 IF
60 (33-79)
51
14
10
I
I
4 (5)a
5 (6)
32 (42)
36 (47)
80%
4 (5)
16 (21)
57 (74)
19 (25)
46 (60)
21 (15)
(SD) was defined as a less than 25% reduction and a less
than 25% increase in this product. Both minor MRs and SD
were pooled into a stable group (ST). All responses and
stabilisation had to be confirmed 4 weeks later without
appearance of new lesions. Finally, progressive disease (PD)
was defined as a > 25% increase in this product or
appearance of new lesions.
Statistics
The two-step Gehan method was used in order to determine
the number of patients required to evaluate the anti-tumour
activity with a P-risk <5% (Gehan et al., 1961). The anti-
tumour activity was expressed as the OR rate (CR + PR) and
95% confidence interval (CI). Comparisons of the incidence
of toxic events or response rates between pretreated patients
and others were made using the chi-square test. Consecutive
assessments of the QL index were analysed using the two-
way analysis of variance and the Newman-Keuls test; this
analysis was done for the entire population and for sub-
groups defined by the response classification. Survival was
defined as the time from the date of induction to the date of
death. Probability of survival was estimated by the Kaplan-
Meier method (Kaplan et al., 1958). Complete response dura-
tion was defined as time from complete response to the time
of progression and partial response duration from first course
of treatment to the time of progression.
Results
Patients' characteristics
Between June 1989 and April 1991, 87 patients from seven
institutions were enrolled (Table I). Of these 77 (88.5%) were
evaluable for response. Ten patients were excluded: two
because of protocol violations, four because of early deaths
unrelated to the disease, three because of early deaths related
to cancer and one because of loss to follow-up. One 79-year-
old patient was included in the analysis despite a minor
protocol violation. Among the 77 evaluable patients, 57
(74%) had metastatic disease; 55 had more than one meta-
static site and 22 (29%) had brain metastases. Among these
22 patients, 12 were evaluable and 10 had received a prior
radiotherapy. As shown in Table I, most of the patients were
pretreated with first-line chemotherapy.
Response
Among the 77 evaluable patients, an objective response was
observed in 13 (17%, 95% CI 9-25%), consisting of one CR
and 12 PRs, and their characteristics are listed in Table II.
Twenty-one (27%) had a stabilisation (1 MR and 20 SD) and
43 (56%) progressed. Median duration of response was 22
weeks (range 7-41 weeks). Of 46 patients who had received
previous chemotherapy, five responded to fotemustine, giving
an OR rate of 11% (95% CI 2-20%), whereas 8 out of 31
non-pretreated patients had a response (OR 26%, CI
10-41%). However, this difference did not reach a statistical
significance (X2 = 2.94). Among the 12 patients with
evaluable brain metastases, we observed two responses (one
complete lasting 11 weeks and one partial lasting 23 weeks).
Twelve patients had liver metastases, but only ten of them
had an evaluable lesion; among these three complete regres-
sions were recorded. Forty-six patients received a main-
tenance therapy with an average of three fotemustine courses
(range 1-13); this population included 13 responding
patients and 21 stable patients. Twelve patients who had a
symptomatic response and experienced no evidence of toxic
effect also received maintenance therapy, although tumour
measurement at week 5 demonstrated progression.
Toxicity
Haematological toxicity was moderate and manageable (Table
III). It consisted mainly of delayed thrombocytopenia
aFour patients had asymptomatic metastatic disease. Abbreviations:
Ad, adenocarcinoma; SQC, squamous cell carcinoma; LCC,
large-cell carcinoma; CT, chemotherapy; RT, radiotherapy; BaC,
bronchioloalveolar carcinoma.1138 J.-L. PUJOL et al.
Table II Characteristics of responding patients
Number
Sex
Median age (range)
Histology
SQC
LCC
Karnofsky index (KI) (%)
100
90
80
70
Median KI for the whole population
Stage of disease
I, II and III
IV
Previous treatment
None
CT ± surgery ± RT
Other than CT
13
13M
61 (38-73)
11
2
9
2
80%
15%
85%
4
5
4
Respondingindicator lesions inmetastatic sites (PR/CR/no. ofpatients
withevaluable indicator lesions)
Liver 0/3/10
Central nervous system 1/1/12
Kidney 1/0/1
Table III Toxicity of fotemustine (% of affected patients)
WHO grade
Toxicity 0 I II III IV NE
Haemoglobin 44 24 18 5 3 6
White cell count 51 15 9 8 1 16
Neutrophil count 57 12 5 7 3 16
Platelet 51 13 7 11 7 11
SGOT 80 7 2 1 0 10
SGPT 77 13 0 0 0 10
Bilirubin 79 6 1 0 0 14
Alkaline phosphatase 63 18 4.5 4.5 10
Creatinine 83 9 0 0 0 8
Nausea, vomiting 79 8 9 3.7 0 0
Abbreviations: SGPT, serum glutamic pyruvic transaminase;
SGOT, serum glutamic oxaloacetic transaminase; NE, not evaluable.
(median nadir day 36) and, to a minor extent, neutropenia.
The incidence of grade III-IV thrombopenia was higher in
pretreated patients than in non-pretreated ones (8% vs 26%,
P<0.05), whereas neutropenia and leucopenia did not
significantly differ. We observed no neutropenia-induced
fever. Three patients required both red blood cell and platelet
transfusions.
Gastrointestinal toxicity was moderate in as much as grade
III nausea and vomiting was only reported in 3.7% of 129
analysed courses; and two patients had diarrhoea. Hepatic
toxicity resulted in a moderate and reversible increase in
SGPT, SGOT, bilirubin and alkaline phosphatase levels, and
none of the patients experienced a grade IV toxicity or a
clinical hepatic toxicity. Moreover, there was only one
patient with a grade III increase in SGOT. In two cases
biological adverse effects might possibly be related to treat-
ment, whereas in the other instances liver metastases and/or
pretreatment might be responsible for these biological
modifications. There was no severe modification of renal
function.
Survival
Median survival of the whole population was 20 weeks
(range 2-111 + weeks; Figure 1). It did not significantly
differ when pretreated patient survival was compared with
other patient survival [median survival of 20 weeks (range
2-91 + weeks) vs 19 weeks (range 2-111) weeks respec-
tively]. Moreover, the subgroup of patients with brain meta-
stases had an identical survival rate. The probability of sur-
vival at 9 and 12 months was 29 and 14% respectively. At
the time of reporting, seven patients had survived for more
than 1 year. Their mean age was 57 years (range 38-73). All
had a stage IV squamous cell carcinoma with a Karnofsky
index of 80%. Four had received chemotherapy prior to
entering this study and four had received brain radiation
therapy for brain metastases. In these seven patients, induc-
tion chemotherapy using fotemustine resulted in a partial
response in five cases and stabilisation in one, whereas the
disease progressed in the remaining patient.
Quality oflife
QL index was reliable and fully analysed in 54 patients. The
mean QL of the whole population decreased slightly during
treatment when comparing day 0 with day 43. However, the
relation of QL versus time was not significant (Figure 2;
P = 0.09). QL index remained stable during the study period
for patients with response or stabilisation, whereas it
significantly decreased (P<0.001) in patients who
experienced progression of the disease. The somatic scale was
fully assessed in 60 patients (69%). This decreased
significantly during the study duration (P = 0.001). However,
in patients with response or stable disease the somatic scale
did not vary according to time (Figure 3). Mean expanded
on-study time was 97 days (range 3-385 days). Only five
patients were admitted for treatment of a toxic event related
to fotemustine. Twenty-nine patients (33%) were never hos-
pitalised, even for fotemustine treatment. This subgroup and
the entire population had a similar duration of on-study time
(90 and 97 days respectively).
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Figure 2 Quality of life index (U, P = 0.09) and somatic scale
(@, P = 0.001) during the induction treatment in the entire
population. Statistics using analysis of variance. Mean and stan-
dard error of the mean are presented.
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Figure 3 Somatic scale during the induction treatment according
to response. Mean somatic evaluations are presented. Analyses of
variance showed a significant decrease in the progression group
(0---0, P<0.001), whereas the variations were non-significant
in both responding ( -0) and stable (Z ~ groups
(P = 0.40).
Discussion
Chemotherapy of NSCLC is still a subject of controversy
(ldhe, 1992). The results of single-drug chemotherapy for this
disease have been extensively reviewed (Bunn, 1991; Donna-
dieu et at., 1991). Few antineoplastic agents allow patients to
achieve more than a 15% OR rate: of these, cisplatin, ifos-
famide, mitomycin, vindesine, vinblastine and, more recently,
vinorelbine (Navelbine) are the most frequently used drugs in
combination. A recent meta-analysis of the randomised trials
comparing chemotherapy and best supportive care in
unresectable NSCLC demonstrated that chemotherapy sig-
nificantly prolongs survival. However, the survival benefit is
probably of modest duration (7-15 weeks), a fact that
accounts for the difficulty in demonstrating a significant
difference in small trials. The QL in patients who undergo
chemotherapy has been, until now, very difficult to report,
and it is not clear whether or not QL is better in
chemotherapy-treated patients (Rapp et at., 1988; Souquet et
at., 1993).
The benefit obtained by the use of chemotherapy in
NSCLC is probably higher in locally advanced disease than
in extensive disease (Pujol et at., 1990; Donnadieu et at.,
1991). Thus, in the setting of locally advanced NSCLC, the
main goal is to improve the rate of cure by including
chemotherapy in combined-modality treatments. On the
other hand, metastatic NSCLC is mainly an incurable disease
for which chemotherapy must reach the best therapeutic
index, i.e. antineoplastic activity without unacceptable toxi-
city. The use of cisplatin-based combinations is unfortunately
limited by the high incidence of digestive toxicity and by the
ineligibility of patients with poor Karnofsky index and/or
renal dysfunction. Thus, for these patients other treatment
modalities must be considered. Finally, it is necessary to
propose treatment to patients with an acceptable Karnofsky
index but poor prognosis, i.e. patients who need a second-
line treatment or patients presenting with brain metastases.
For these patients the choice should be a compromise
between potential benefit in survival and QL and decrease in
hospitalisation and cost. However, until now, most of the
new drugs have been investigated as first-line treatment,
whereas others are inefficient as second-line therapy. Thus,
new active drugs in patients with poor prognostic factors are
needed because their treatment is a frequent problem in
current practice.
The present study demonstrates the feasibility of a
chemotherapy regimen consisting of fotemustine 100 mg m 2
administered on a day 1 and 8 schedule. It is noteworthy that
the inclusion criteria of this trial matched the characteristics
of the patient population admitted into our institutions, in
particular pretreated patients or patients with central nervous
system metastases. Both features, usually excluded from con-
ventional chemotherapy trials, were eligible in this study and
the results in these subgroups were good even though they
were slightly lower than in other patients. Overall toxicity
can be considered as mild to moderate and manageable. The
low haematological toxicity, even in pretreated patients, and
the low gastrointestinal, hepatic and renal toxicities make it
possible to propose fotemustine as a treatment for poor-
prognosis NSCLC even though renal function is impaired. Of
interest, there was no major modification of the QL index
during the study and the somatic scale proposed by this
study only decreased in patients who progressed during the
treatment. Thus, fotemustine seems not to impair the QL.
To be considered as active, an antineoplastic drug must
produce a response rate > 15% (Hansen, 1988). Both re-
sponse rate and response duration observed in this study
were over this limit. Fotemustine had, therefore, a good
therapeutic index in as much as the 17% OR rate is
associated with neither life-threatening toxic events nor
impairment of the QL and is an applicable treatment in
poor-prognosis NSCLC. Our results deserve further evalua-
tion of fotemustine in combination with other active drugs in
NSCLC.
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